Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968733 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
A Phase 3 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 863
- Enrollment target
NCT01968733 is a Phase 3 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 863 participants.
The verdict
NCT01968733, a Phase 3 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 863 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
Interventions
- DRUG Moxifloxacin
- DRUG Solithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 863 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968733
The ClinicalTrials.gov registry entry for NCT01968733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 863 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Moxifloxacin is the first listed.
NCT01968733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01968733 about?
NCT01968733 is a clinical study titled "Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia". This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
What is the current status of trial NCT01968733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 863 participants. The study started on 2013-11. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01968733?
The interventions under investigation include: Moxifloxacin (DRUG), Solithromycin (DRUG).
Who is sponsoring clinical trial NCT01968733?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.